We have observed
11 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
January 19, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
CLAY-BASED AROMATISED THERAPEUTIC COMPOSITION
MACROCYCLIC LRRK2 KINASE INHIBITORS
PROCESS FOR THE SYNTHESIS OF THERAPEUTIC PEPTIDES
Pharmaceutical composition for a sustained release of lanreotide
Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
AQUEOUS GELLING COMPOSITIONS OF SOLUBLE ACTIVE PHARMACEUTICAL PEPTIDES PROVIDING MODIFIED RELEASE
AQUEOUS SUSTAINED RELEASE COMPOSITIONS OF LHRH ANALOGUES
PHARMACEUTICAL COMPOSITION FOR A SUSTAINED RELEASE OF LANREOTIDE
COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD1 AND/OR PDL1 INHIBITOR, FOR USE AS A MEDICAMENT
SUSTAINED RELEASE FORMULATIONS COMPRISING VERY LOW MOLECULAR WEIGHT POLYMERS
COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT